NPCE
NeuroPace Inc

331
Mkt Cap
$437.67M
Volume
302,257.00
52W High
$18.98
52W Low
$7.56
PE Ratio
-19.70
NPCE Fundamentals
Price
$13.00
Prev Close
$13.13
Open
$13.02
50D MA
$15.16
Beta
1.14
Avg. Volume
160,402.77
EPS (Annual)
-$0.656
P/B
22.93
Rev/Employee
$478,401.91
$515.01
Loading...
Loading...
News
all
press releases
NeuroPace (NASDAQ:NPCE) Upgraded at Wells Fargo & Company
Wells Fargo & Company upgraded shares of NeuroPace to a "strong-buy" rating in a research report on Wednesday...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
NeuroPace (NASDAQ:NPCE) Stock Rating Lowered by Wall Street Zen
Wall Street Zen cut NeuroPace from a "buy" rating to a "hold" rating in a research note on Sunday...
MarketBeat·7d ago
News Placeholder
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026
NPCE heads into 2026 with 20%+ RNS growth targets, higher Medicare reimbursement and a cleaner revenue mix as the DIXI distribution business rolls off.
Zacks·11d ago
News Placeholder
NPCE RNS System Explained: Growth Drivers and Setup for 2026
NPCE enters 2026 with rising RNS adoption, stronger margins and Medicare payment hikes that could boost hospital economics for replacement procedures.
Zacks·11d ago
News Placeholder
NeuroPace's Seizure ID and New Indication Could Expand RNS Demand
NPCE's Seizure ID AI tool and potential idiopathic generalized epilepsy approval could expand RNS adoption as NeuroPace pushes software-driven care in 2026.
Zacks·11d ago
News Placeholder
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Brokerages
NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are covering the stock, MarketBeat reports. One research...
MarketBeat·15d ago
News Placeholder
NeuroPace (NASDAQ:NPCE) Upgraded to "Buy" at Wall Street Zen
Wall Street Zen upgraded NeuroPace from a "hold" rating to a "buy" rating in a research report on Saturday...
MarketBeat·15d ago
News Placeholder
NeuroPace to Present at the Leerink Global Healthcare Conference
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink 2026...
Business Wire·16d ago
News Placeholder
NeuroPace (NASDAQ:NPCE) Stock Rating Upgraded by Cantor Fitzgerald
Cantor Fitzgerald upgraded shares of NeuroPace to a "strong-buy" rating in a report on Wednesday...
MarketBeat·17d ago
News Placeholder
Why NeuroPace Stock Was Inching Higher on Wednesday
Key PointsThe niche medical devices specialist published its latest quarterly and annual fundamentals...
Nasdaq News: Markets·17d ago
<
1
2
...
>

Latest NPCE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.